Back to List View Graph View

Protein tyrosine phosphatase non-receptor type 1 (PTPN1)

Protein tyrosine phosphatase non-receptor type 1 (PTPN1), commonly known as protein tyrosine phosphatase 1B (PTP1B), is a non-receptor protein tyrosine phosphatase that functions as a key negative regulator of signaling pathways mediated by receptor tyrosine kinases.

Where the papers sit

13 papers from the last 6 months study Protein tyrosine phosphatase non-receptor type 1 (PTPN1) directly · updated from PubMed 10 Nov 2026

Study type 0 clinical trials · 3 human data · 10 preclinical

Themes 3 themes · 1 new direction

  • Phosphatase Inhibitors in Cancer

    Allosteric phosphatase inhibitors are being developed to disrupt RAS-driven and gastric cancer signaling. SHP2 and PTP1B programs repeatedly connect inhibition with PI3K/AKT, STAT3, migration, apoptosis and broader antiproliferative effects. Selective small molecules are advancing alongside macrocyclic ligands and computationally guided natural-product leads. The main open issue is whether multi-pathway activity can translate into selective antitumor efficacy.

    5 papers · 38.5%

  • PTP1B Inhibitor Discovery

    PTP1B inhibition is being pursued across glucose control and breast cancer. Cholic acid derivatives and dual DPP-4/PTP1B inhibitors aim to improve hypoglycemic activity, while plant extracts provide additional enzyme-inhibitory leads. In breast cancer, p-propoxybenzoic acid is linked to PTP1B inhibition and reduced DMBA-associated disease. The field is moving toward multi-target and structure-guided inhibitor development.

    4 papers · 30.8%

  • PTP1B in Inflammatory Disease

    PTP1B is being linked to inflammatory and stress-related injury across the brain, retina and metabolic disease. Inhibition is explored for Alzheimer’s disease and diabetic retinal neurodegeneration, where oxidative stress, myeloid signaling and apoptosis recur. miR-329-3p adds a biomarker and neuroprotection angle in ischemic stroke, while GLP-1R and IL-17A targeting addresses obesity-associated leukemia. The cluster supports PTP1B as a disease-modifying axis but does not establish one unified treatment strategy.

    4 papers · 30.8%

NEW DIRECTION

PTP1B can serve as a noninhibitory proximity-recruitment handle rather than only as an enzyme to inhibit

The function-based screening study of PTP1B using bead-displayed macrocycles 42504525Jul challenges the assumption, shared by the other papers, that PTPN1/PTP1B is useful chiefly when its phosphatase activity is blocked. It identified macrocyclic ligands that engage PTP1B without inhibiting it and demonstrated a screening strategy intended to recruit the enzyme for chemically induced proximity and other functional manipulations. This recasts PTP1B from a conventional inhibitory drug target into a programmable molecular component whose preserved activity can be exploited.

Papers

The 13 papers from the last 6 months that study Protein tyrosine phosphatase non-receptor type 1 (PTPN1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Phosphatase Inhibitors in Cancer (5)
  1. Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Cancer. Chemistry & biodiversity · 30 Sept 2026 PMID 42814531
  2. Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593923
  3. Mechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer: Multi-pathway signaling modulation in vitro. PloS one · 30 Jul 2026 PMID 42531194
  4. Discovery of Noninhibitory Macrocyclic Ligands for Protein Tyrosine Phosphatase 1B Using a Function-Based, Iterative Screening Strategy. Journal of the American Chemical Society · 27 Jul 2026 PMID 42504525
  5. Allosteric PTP1B inhibition as a source of multi-mechanistic anti-tumor activity. Bioorganic chemistry · 19 Jun 2026 PMID 42320116
PTP1B Inhibitor Discovery (4)
  1. Interceptive effect of p-propoxybenzoic acid against DMBA-induced breast cancer in female sprague dawley rats through PTP1B inhibition. Medical oncology (Northwood, London, England) · 9 Nov 2026 PMID 43002335
  2. Bioactive Properties of Achillea biserrata M.Bieb. Extracts: Phytochemical Analysis, Antioxidant Activity, Target Enzyme Inhibition, and Cytotoxic Effects. Chemistry & biodiversity · 31 Aug 2026 PMID 42672901
  3. Structure-Based De Novo Design of Novel Dual DPP IV and PTP 1B Inhibitors (DDPI's). Chemistry & biodiversity · 30 Jun 2026 PMID 42378400
  4. Cholic acid derivatives as novel PTP1B inhibitors: Their synthesis, inhibition mechanism, and hypoglycemic effects. European journal of medicinal chemistry · 19 Jun 2026 PMID 42320200
PTP1B in Inflammatory Disease (4)
  1. Serum miR-329-3p as a potential biomarker for ischemic stroke: clinical association and in vitro neuroprotection via PTPN1. Metabolic brain disease · 19 Oct 2026 PMID 42895677
  2. Targeting the protein tyrosine phosphatase 1B signaling axis in Alzheimer's disease: Emerging therapeutic potential of ivermectin. Biochemical and biophysical research communications · 3 Sept 2026 PMID 42691626
  3. Targeting GLP-1R and IL-17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model. The Journal of clinical investigation · 23 Jun 2026 PMID 42334870
  4. Myeloid Cell Protein Tyrosine Phosphatase 1B Drives Retinal Neurodegeneration in Diabetic Mice. Diabetes · 21 May 2026 PMID 42166617

By study type

Human data, design not indexed (3)
  1. Serum miR-329-3p as a potential biomarker for ischemic stroke: clinical association and in vitro neuroprotection via PTPN1. Metabolic brain disease · 19 Oct 2026 PMID 42895677
  2. Discovery of Noninhibitory Macrocyclic Ligands for Protein Tyrosine Phosphatase 1B Using a Function-Based, Iterative Screening Strategy. Journal of the American Chemical Society · 27 Jul 2026 PMID 42504525
  3. Structure-Based De Novo Design of Novel Dual DPP IV and PTP 1B Inhibitors (DDPI's). Chemistry & biodiversity · 30 Jun 2026 PMID 42378400
Preclinical: animal, cell and lab studies (10)
  1. Interceptive effect of p-propoxybenzoic acid against DMBA-induced breast cancer in female sprague dawley rats through PTP1B inhibition. Medical oncology (Northwood, London, England) · 9 Nov 2026 PMID 43002335
  2. Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Cancer. Chemistry & biodiversity · 30 Sept 2026 PMID 42814531
  3. Targeting the protein tyrosine phosphatase 1B signaling axis in Alzheimer's disease: Emerging therapeutic potential of ivermectin. Biochemical and biophysical research communications · 3 Sept 2026 PMID 42691626
  4. Bioactive Properties of Achillea biserrata M.Bieb. Extracts: Phytochemical Analysis, Antioxidant Activity, Target Enzyme Inhibition, and Cytotoxic Effects. Chemistry & biodiversity · 31 Aug 2026 PMID 42672901
  5. Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593923
  6. Mechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer: Multi-pathway signaling modulation in vitro. PloS one · 30 Jul 2026 PMID 42531194
  7. Targeting GLP-1R and IL-17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model. The Journal of clinical investigation · 23 Jun 2026 PMID 42334870
  8. Cholic acid derivatives as novel PTP1B inhibitors: Their synthesis, inhibition mechanism, and hypoglycemic effects. European journal of medicinal chemistry · 19 Jun 2026 PMID 42320200
  9. Allosteric PTP1B inhibition as a source of multi-mechanistic anti-tumor activity. Bioorganic chemistry · 19 Jun 2026 PMID 42320116
  10. Myeloid Cell Protein Tyrosine Phosphatase 1B Drives Retinal Neurodegeneration in Diabetic Mice. Diabetes · 21 May 2026 PMID 42166617